


AMENDMENTS TO THE CLAIMS

1. (Original) A fused bicyclic pyridine derivative represented by the following general formula (1), or a salt thereof:



wherein the rings A and B are each a benzene ring, which may have 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring) that are each independently selected from the group consisting of a halogen atom, a substituted or unsubstituted C₁ to C₆ alkyl group, and a substituted or unsubstituted C₁ to C₆ alkoxy group;


R is a C₁ to C₆ alkylsulfonyl group, a C₁ to C₆ alkylcarbonyl group, a C₁ to C₆ alkoxy carbonyl group, or a formyl group;

m is 1 or 2;

n is 2 or 3; and

q is 1 or 2.

2. (Original) The fused bicyclic pyridine derivative according to claim 1, represented by the following general formula (1a), or a salt thereof:



wherein the ring A is a benzene ring, which may have 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring) that are each independently selected from the group consisting of a halogen atom, a substituted or unsubstituted C₁ to C₆ alkyl group, and a substituted or unsubstituted C₁ to C₆ alkoxy group;

R is a C₁ to C₆ alkylsulfonyl group, a C₁ to C₆ alkylcarbonyl group, a C₁ to C₆ alkoxy carbonyl group, or a formyl group;

m is 1 or 2;

n is 2 or 3; and

q is 1 or 2.

3. (Original) The fused bicyclic pyridine derivative according to claim 2, or a salt thereof, wherein in the general formula (1a) above, n is 3.
4. (Original) The fused bicyclic pyridine derivative according to claim 2, or a salt thereof, wherein in the general formula (1a) above, R is an acetyl group and n is 3.
5. (Original) The fused bicyclic pyridine derivative according to claim 2, or a salt thereof, wherein in the general formula (1a) above, R is an acetyl group, n is 3, and q is 1.
6. (Currently Amended) A tachykinin receptor antagonist containing as an active ingredient the fused bicyclic pyridine derivative according to ~~any one of claims 1 to 5~~ claim 1, or a salt thereof.
7. (Currently Amended) An NK1 receptor antagonist containing as an active ingredient the fused bicyclic pyridine derivative according to ~~any one of claims 1 to 5~~ claim 1, or a salt thereof.
8. (Currently Amended) A prophylactic or therapeutic agent for dysuria, including defective bladder functions such as increased urinary frequency and incontinence of urine, containing as an active ingredient the fused bicyclic pyridine derivative according

to ~~any one of claims 1 to 5~~ claim 1, or a salt thereof.

9. (Currently Amended) A prophylactic or therapeutic agent for disorders of digestive tract such as ulcerative colitis and Crohn's disease, containing as an active ingredient the fused bicyclic pyridine derivative according to ~~any one of claims 1 to 5~~ claim 1, or a salt thereof.

10. (Currently Amended) A prophylactic or therapeutic agent for vomiting induced by exposure to X-ray, chemotherapy, pregnancy, migraine, postoperative pains, decreased gastrointestinal motility, and side effects of drugs, containing as an active ingredient the fused bicyclic pyridine derivative according to ~~any one of claims 1 to 5~~ claim 1, or a salt thereof.

11. (Currently Amended) A therapeutic agent for treating conditions, such as asthma, coughing, ache, migraine, tooth pain, and rheumatoid arthritis, containing as an active ingredient the fused bicyclic pyridine derivative according to ~~any one of claims 1 to 5~~ claim 1, or a salt thereof.